Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib, and Pirtobrutinib is a highly selective and non-covalent next generation BTK inhibitor. Pirtobrutinib (LOXO-305) effectively inhibits diverse BTK C481 substitution mutations[1].
Description | (R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib, and Pirtobrutinib is a highly selective and non-covalent next generation BTK inhibitor. Pirtobrutinib (LOXO-305) effectively inhibits diverse BTK C481 substitution mutations[1]. |
Molecular Weight | 479.436 |
Formula | C22H21F4N5O3 |
CAS No. | 2101700-14-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 200 mg/mL (417.16 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(R)-Pirtobrutinib 2101700-14-3 (R)Pirtobrutinib Pirtobrutinib (R) Pirtobrutinib inhibitor inhibit